Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2024 Earnings Call Transcript March 4, 2025
Esperion Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.14.
Operator: Ladies and gentlemen, thank you for standing by and welcome. [Operator Instructions] Please be advised that today’s conference call may be recorded. I would now like to turn the call over to Alina Venezia, Director of Investor Relations for Esperion Therapeutics. You may begin.
Alina...
